Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Injectable platelet-rich fibrin is better than platelet-rich plasma for promoting hair growth.

Increased IGF-1R expression is linked to thicker skin growth.

IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.

TGF-beta 1 and IGF-II mRNA have specific patterns in pig subcutaneous tissue, affecting fat and muscle development.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

IGFBP-rP1 could be a new treatment for a common type of hair loss.

Oleuropein increases IGF-1 levels in mouse skin.

Overexpressing IGF-1 in mice leads to skin abnormalities and tumors.

Pro-Ile could be used in cosmetics to improve skin, hair growth, and healing.

iL-PRF treatment improves hair growth for androgenetic alopecia.

A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.

Reducing IGF-1 can help rejuvenate hair follicles and prevent hair graying and loss.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Higher IGF-1 levels in hair follicles link to better finasteride results for hair loss.

A new drug delivery system using oil body-bound oleosin-rhFGF-10 improves wound healing and hair growth in mice.

The peptide GPIGS helps hair cells grow and speeds up hair regrowth in mice.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

IPM enhances skin penetration of hydrophilic drugs.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

IGF-1 increases whisker growth in transgenic mice.

Overexpression of LRIG3 in skin causes hair loss.

Targeting the HEDGEHOG-GLI1 pathway could help treat keloids.

A sphingolipid from human placenta may help treat vitiligo by activating melanocyte stem cells.

Retinoic acid, glucocorticoids, and IGF1 increase IGFBP-3 production in human dermal papilla cells, affecting hair growth.

Correct diagnosis and treatment are crucial for effective management of lipid storage myopathies.

Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.

EGF, IGF-I, and IGF-IR genes are crucial for mink skin and hair growth.